Thompson Bruce Robert, Westall Glen Philip, Paraskeva Miranda, Snell Gregory Ian
Lung Transplant Service, Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia.
Respirology. 2014 Nov;19(8):1097-105. doi: 10.1111/resp.12370. Epub 2014 Sep 3.
The number of lung transplants performed globally continues to increase year after year. Despite this growing experience, long-term outcomes following lung transplantation continue to fall far short of that described in other solid-organ transplant settings. Chronic lung allograft dysfunction (CLAD) remains common and is the end result of exposure to a multitude of potentially injurious insults that include alloreactivity and infection among others. Central to any description of the clinical performance of the transplanted lung is an assessment of its physiology by pulmonary function testing. Spirometry and the evaluation of forced expiratory volume in 1 s and forced vital capacity, remain core indices that are measured as part of routine clinical follow-up. Spirometry, while reproducible in detecting lung allograft dysfunction, lacks specificity in differentiating the different complications of lung transplantation such as rejection, infection and bronchiolitis obliterans. However, interpretation of spirometry is central to defining the different 'chronic rejection' phenotypes. It is becoming apparent that the maximal lung function achieved following transplantation, as measured by spirometry, is influenced by a number of donor and recipient factors as well as the type of surgery performed (single vs double vs lobar lung transplant). In this review, we discuss the wide range of variables that need to be considered when interpreting lung function testing in lung transplant recipients. Finally, we review a number of novel measurements of pulmonary function that may in the future serve as better biomarkers to detect and diagnose the cause of the failing lung allograft.
全球范围内进行的肺移植数量逐年持续增加。尽管有了越来越多的经验,但肺移植后的长期结果仍远低于其他实体器官移植的情况。慢性肺移植功能障碍(CLAD)仍然很常见,它是暴露于多种潜在有害因素(包括同种异体反应性和感染等)的最终结果。对移植肺的临床性能进行任何描述的核心都是通过肺功能测试来评估其生理学。肺活量测定以及对一秒用力呼气量和用力肺活量的评估,仍然是作为常规临床随访一部分进行测量的核心指标。肺活量测定虽然在检测肺移植功能障碍方面具有可重复性,但在区分肺移植的不同并发症(如排斥反应、感染和闭塞性细支气管炎)方面缺乏特异性。然而,肺活量测定的解读对于定义不同的“慢性排斥反应”表型至关重要。越来越明显的是,通过肺活量测定所测得的移植后达到的最大肺功能受到许多供体和受体因素以及所进行的手术类型(单肺移植、双肺移植还是肺叶移植)的影响。在这篇综述中,我们讨论了在解读肺移植受者的肺功能测试时需要考虑的广泛变量。最后,我们回顾了一些新的肺功能测量方法,这些方法未来可能作为更好的生物标志物来检测和诊断肺移植失败的原因。